Etanercept News and Research RSS Feed - Etanercept News and Research

Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune system) by acting as a TNF inhibitor.
New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016

Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures. [More]
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met. [More]
Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that a range of factors other than just cost may influence the prescribing of TNF inhibitors for patients with rheumatoid arthritis (RA). [More]
Antiinflammatory drug HUMIRA enhances specific TNF function in rheumatoid arthritis patients

Antiinflammatory drug HUMIRA enhances specific TNF function in rheumatoid arthritis patients

Researchers from University College London have discovered that the widely used antiinflammatory drug HUMIRA doesn't just work by inhibiting its target protein, TNF, but by enhancing a particular function of TNF in rheumatoid arthritis patients. [More]
Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy. [More]
New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

About half of Medicare patients who start taking biologic therapies for moderate to severe plaque psoriasis stop within a year, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. [More]
Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Eli Lilly and Company announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab in a Phase 3 clinical trial. Detailed results of the UNCOVER-2 study were presented during the American Academy of Dermatology Annual Meeting taking place March 4-8 in Washington, D.C. [More]
Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Eli Lilly and Company announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for ixekizumab for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union who are candidates for systemic therapy. [More]
BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel. [More]
New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

The new BSR guidelines make a number of specific recommendations for the use of standard and/or biologic disease modifying anti-rheumatic drugs (DMARDs), providing crucial advice for clinicians, obstetricians and midwives. [More]
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel (etanercept) - a tumor necrosis factor alpha (TNF-α) inhibitor [More]
Study: New test may help predict effectiveness of biologic drugs in RA patients

Study: New test may help predict effectiveness of biologic drugs in RA patients

A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them. [More]
Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study shows that TNFi dose reduction strategy can help in optimal management of RA

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third. [More]
Ixekizumab drug shows quick and extensive improvements in patients with psoriasis

Ixekizumab drug shows quick and extensive improvements in patients with psoriasis

A University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement. [More]

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for SB2, its Remicade (Infliximab) biosimilar candidate, has been submitted to the European Medicines Agency (EMA). [More]
Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets. [More]
Australian Prescriber publishes top 10 subsidised drugs in Australia

Australian Prescriber publishes top 10 subsidised drugs in Australia

The annual publication of the top 10 subsidised drugs appears in the December edition of Australian Prescriber. Statins (cholesterol-lowering medicines) top the lists again. [More]
Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis. [More]
Phase III research shows that new drug improves symptoms related to plaque psoriasis

Phase III research shows that new drug improves symptoms related to plaque psoriasis

Randomized, phase III research from the University of Alabama at Birmingham shows that a new drug improves symptoms related to moderate to severe plaque psoriasis, a chronic skin disease of scaling and inflammation. [More]
Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) demonstrate the possibility of using biomarkers (developed from whole blood gene expression profiles) in children with juvenile idiopathic arthritis (JIA) to predict the status of their disease at 12 months. [More]
Advertisement
Advertisement